




Oxymetazoline

Revised: March 17, 2021.

CASRN: 1491-59-4



Drug Levels and Effects

Summary of Use during Lactation

Although no information exists on the use of oxymetazoline specifically during breastfeeding, very little should reach the infant through breastmilk because of the local administration and limited absorption into the maternal bloodstream. It is recommended over oral systemic decongestants such as pseudoephedrine during breastfeeding.[1] Topical use on the face is unlikely to present a risk to the nursing infant.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

References

1. Anderson PO. Decongestants and milk production. J Hum Lact 2000;16:294. Letter. PMID: 11155604

Substance Identification

Substance Name

Oxymetazoline

CAS Registry Number

1491-59-4

Drug Class

Breast Feeding

Lactation

Adrenergic alpha-Agonists

Sympathomimetics

Nasal Decongestants